Phase II randomized, double-blind, placebo-controlled trial of CDI-45205 in non-hospitalized patients with mild or moderate COVID-19
Latest Information Update: 09 Dec 2021
At a glance
- Drugs CDI-45205 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Cocrystal Pharma Inc
- 09 Dec 2021 New trial record